Construction method and application of spontaneous atopic dermatitis animal model
By overexpressing the Tslp gene in NCG of severely immunodeficient mice and transplanting human cells, a mouse model of the humanized immune system was constructed, and the problem that the existing model could not stimulate dermatitis in a specific pathogen-free environment was solved, and the problem of the existing model being unable to stimulate dermatitis in a specific pathogen-free environment was achieved. The effect of spontaneously generating AD-like symptoms and accurately simulating clinical pathological characteristics in a standardized environment.
Patent Information
- Application Number
- CN202310537713.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-15
AI Technical Summary
The existing animal models of spontaneous atopic dermatitis cannot stimulate dermatitis manifestations in specific pathogenic environments, and the model constructed by exogenous sensitization cannot accurately reflect the role of gene drivers in the pathogenesis of the disease, leading to preclinical trial results Inconsistent with the human body.
The NCG of severely immunodeficient mice overexpressed the Tslp gene through gene editing technology and transplanted human PBMC or HSC to build a humanized immune system, establish a Tslp transgenic mouse model, simulate the human immune system, and spontaneously produce AD-like symptoms.
Spontaneously generate AD-like symptoms in a standardized environment, simulate clinical pathological characteristics, improve the scientificity and accuracy of drug efficacy experiments, avoid species differences between humans and mice, and fill the gap in domestic AD transgenic models.
Smart Images

Figure CN118956952A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of animal genetic engineering and gene genetic modification, and specifically relates to a method for constructing a spontaneous atopic dermatitis animal model and its application. Background Art
[0002] Atopic dermatitis (AD), also known as atopic dermatitis, is a common chronic inflammatory skin disease. The clinical manifestations are severe itching, exudative tendency and eczematous skin lesions, and this disease often has a high probability of atopic manifestations such as allergic rhinitis, asthma, and food allergies. Epidemiological results show that the current incidence of AD is distributed regionally, with the highest prevalence of AD in Nordic countries. With the development of urbanization, the incidence of AD in my country has also been on the rise in recent years. Among them, the prevalence in children has exceeded 20%, and the prevalence in adults is 3%-5%. Due to the significant itching of AD patients, it often causes insomnia, irritability and other mental and emotional changes, which seriously affects the daily life and work of patients and their families, and brings huge burdens to patients and families. At present, clinical treatment options for AD have not fully met major medical needs, so research and exploration of AD treatment methods has not stopped.
[0003] The pathogenesis of AD is complex, involving multiple factors such as genetics, immunity, skin barrier, and environment, among which immune dysfunction is the central link in the onset of AD. AD has a strong Th2 component associated with overexpression of IL-4 and IL-13, which manifests as an exaggerated Th2-type inflammatory response. Th1 / Th2 imbalance accompanied by increased production of Th2-type cytokines is the main pathogenesis of AD. The key upstream regulator of Th2 response is thymic stromal lymphopoietin (Tslp). Tslp is an epithelial-derived cytokine with a wide range of target cells, which can act on dendritic cells, T cells, B cells, neutrophils, mast cells, eosinophils, and innate lymphoid cells. As part of the innate immune response, Tslp regulates dendritic cells and induces the differentiation of initial T cells into inflammatory Th2 cells, and promotes the secretion of cytokines by mast cells, eosinophils, and macrophages. Tslp has been considered a catalyst for type 2 inflammatory-related diseases such as atopic dermatitis. Related studies have found high levels of Tslp expression in AD lesion skin tissue, indicating that Tslp plays an important role in the occurrence and development of AD. In addition, Th17 cells are a new type of helper T cells, and IL-23 regulates the differentiation of Th17 cells. Activated Th17 cells secrete cytokines and chemokines such as IL-17, IL-21, IL-22, and IL-23, which play a pro-inflammatory and immunomodulatory role. Studies have found that the expression of Th17-related cytokines and regulatory factors in AD increases, which is positively correlated with the severity of the disease. IL-17 can accelerate the production of IgE and directly play a pro-allergic role at the B cell level. It can also promote the secretion of Th2 cytokines such as IL-4 and IL-13, aggravating the inflammatory response of AD. Related studies have confirmed that Tslp is involved in the differentiation of Th17 cells and the inflammatory process driven by Th17.
[0004] More and more institutions are beginning to pay attention to the research and development of drugs for AD treatment. The new drug development process generally includes selecting drug targets, selecting candidate drugs, conducting effectiveness and safety evaluation on experimental animals, and conducting clinical trials on humans.
[0005] The Nc / Nga mouse and Ds-NH mouse models developed by Japanese scholars are currently ideal spontaneous animal models for studying AD. However, the spontaneous AD-like mice must be placed in a normal environment to induce AD symptoms. In a specific pathogen-free SPF-level breeding environment, the expected dermatitis symptoms will not appear, and no itching symptoms have been observed in mice. This undoubtedly brings great inconvenience to the standardized and unified management of animals. In addition, exogenous chemical substances, dust mites, superantigens (Staphylococcus aureus enterotoxin), ovalbumin (OVA), capsaicin and other substances are used to induce AD. However, the AD model constructed by this type of exogenous sensitization method cannot accurately reflect the relevant role of gene drive in the pathogenesis of AD, but is relatively focused on responding to the immune inflammatory response induced by exogenous antigens.
[0006] Due to species differences, there are still certain differences between the model animals and the human physiological immune system. Therefore, the therapeutic effects observed in preclinical animal trials may not be consistent with those of clinical patients. Summary of the invention
[0007] In view of the deficiencies in the prior art, the present invention utilizes severely immunodeficient mice NCG, which have defects in T, B and NK cells and are ideal mouse models for reconstructing the human immune system. Transgenic technology is used to overexpress the mouse Tslp gene in mice with an NCG background to establish NCG-mTslp transgenic mice, and the transgenic mice are further immune reconstructed and transplanted with human PBMC or HSC to construct an NCG-mTslp animal model with a humanized immune system, thereby making the pathogenic mechanism and efficacy experiments of atopic dermatitis more objective and scientific.
[0008] The specific technical solutions of the present invention are as follows:
[0009] A method for constructing a Tslp transgenic animal model, using gene editing technology to overexpress the Tslp gene in immunodeficient animals.
[0010] In the method of the present invention, the immunodeficient animal is preferably an NCG in NOD background in which the Prkdc and Il2rg genes are knocked out using gene editing technology (NOD / ShiLtJGpt-Prkdc em26Cd52 Iq em26Cd22 / Gpt) mice. The functional loss of the Prkdc gene in NCG mice results in the failure of V(D)J recombination to occur normally, resulting in the failure of T cells and B cells to mature. IL2RG is a common subunit of multiple interleukin cytokine receptors. The inactivation of IL2RG leads to the loss of multiple different cytokine signaling pathways, resulting in NK cell defects. Therefore, NCG is one of the most thorough mouse models of immune system deficiency to date, and is very suitable for immune reconstruction by transplantation of human peripheral blood mononuclear cells (PBMC) and human hematopoietic stem cells (HSC).
[0011] The construction method described in the present invention, the gene editing technology includes one or more of homologous recombination, zinc finger nuclease technology, transcription activator-like effector nuclease technology, CRISPR / Cas9 system, and single base editing technology.
[0012] A preferred example of the present invention is to use gene editing technology to obtain a transgenic targeting vector, inject the targeting vector into an animal fertilized egg by microinjection, or transfect the targeting vector into an animal ES cell by ES cell targeting technology, or recombinantly reconstitute the target gene into a retroviral vector by retroviral infection method, infect animal embryos before / after implantation, or introduce the transgenic targeting vector into sperm by electroporation by sperm vector method and then combine it with the egg. Specifically, the following steps are included:
[0013] (1) Design and construct a targeting donor containing the protein coding region of the Tslp gene;
[0014] (2) injecting the target donor prepared in step (1) into the fertilized egg of an immunodeficient animal or transfecting it into the ES cell of an immunodeficient animal by microinjection, and randomly inserting the protein coding region of the Tslp gene into the genome;
[0015] (3) Transplanting the fertilized egg into a surrogate mother or injecting the targeted positive ES cells into the animal blastocyst and then transplanting the blastocyst into the surrogate mother for breeding. The offspring produced are the F0 generation animals. After the F0 generation animals with correct genotype identification reach sexual maturity, they are bred with wild-type animals of the same background to obtain the F1 generation;
[0016] The protein coding region sequence of the Tslp gene is shown in SEQ ID NO:1.
[0017] Considering that Tslp is usually expressed in epithelial cells on the surface of lung, skin and intestinal barrier, and the keratin 14 (K14) promoter is mainly expressed in epithelial cells, the K14 promoter was chosen to drive the expression of Tslp.
[0018] In a preferred technical solution of the present invention, the targeting donor includes keratin promoter K14, mTslp CDS and transcription terminator. The transcription terminator can be SV40, hGH, BGH or rbGlob. In a specific example, the transcription terminator is Human GH polyA.
[0019] The specific operation of constructing the targeting donor is: using VEGFR3-TG-Final as a template to amplify hk14, mTslp CDS as a template to amplify mTslp, using Human GH CDS as a template, high-fidelity enzyme PCR to amplify hGH, using pMD18-T as a template to amplify the pMD18-T vector, and slicing the above four fragments to construct the vector. The targeting vector was transferred into the competent state Top10 for positive clone identification. The plasmid was further extracted for enzyme digestion identification. NotI digestion and electrophoresis were performed to recover the correct fragment (3666bp fragment was recovered), purified, and the targeting donor was obtained for injection.
[0020] In a specific technical solution of the present invention, the targeting donor sequence is shown in SEQ ID NO: 2. Among them, flangking: 1bp-50bp, 3609bp-3658bp; human keratin promoter: 51bp-2550bp; mTslp CDS: 2551bp-2973bp; hGH polyA: 2974-3608bp.
[0021] In the construction method of the present invention, the animal is a mammal, preferably a rodent, more preferably a rat or a mouse. In a preferred embodiment, the mouse is a severely immunodeficient mouse NCG (Hao M, Hou S, Li W, Li K, et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Transl Med. 2020 Nov 25; 12(571): eaaz6667.).
[0022] Another object of the present invention is to provide a method for constructing a spontaneous atopic dermatitis animal model, wherein the immune system of the Tslp transgenic animal model constructed by the aforementioned method of the present invention is reconstructed, and human stem cells with differentiation potential are transplanted into the model to construct a spontaneous atopic dermatitis animal model.
[0023] In the method of the present invention, the immune system reconstruction is performed by bone marrow stem cell elimination or immunosuppression and immunoregulation using low-toxic drugs. Bone marrow hepatocyte elimination is performed by sublethal doses of ionizing radiation or chemical means to eliminate hematopoietic stem cells in the bone marrow of animals. The use of low-toxic drugs is the use of drugs that inhibit stem cell proliferation or block differentiation information conduction (such as imatinib, etc.) for immunosuppression and immunoregulation.
[0024] The method of removing hematopoietic stem cells from the bone marrow of an animal by ionizing radiation or chemical means of the present invention can adopt the types, doses and operation methods conventionally used in the prior art. For example, the ionizing radiation is X-ray or Co60 irradiation, the irradiation dose is 80 to 100 cGy, or a higher sublethal dose, and the chemical means is to give the animal one or more of busulfan, cyclophosphamide, and melphalan. Taking busulfan as an example, myeloablative preconditioning can be completed by connecting intraperitoneal injections at a dose of 20 mg / kg for 24 hours (Encarnacion Montecino-Rodriguez, et al., STAR Protocols, 2020.).
[0025] Stem cells with differentiation potential are stem cells that can differentiate into a variety of immune cells, and can further be one or more of bone marrow cells, fetal liver cells, hematopoietic stem cells, pluripotent stem cells, and induced pluripotent stem cells, preferably bone marrow cells or hematopoietic stem cells. The stem cells can be freshly isolated cells or cells that have been revived after freezing.
[0026] In a specific technical solution of the present invention, immune system reconstruction comprises the following steps:
[0027] (1) 3-4 week old female Tslp transgenic severely immunodeficient mice NCG were irradiated with 80-100 cGy for myeloablation;
[0028] (2) Human hematopoietic stem cells hCD34 + HSCs were inoculated into mice via the tail vein at a dose of 5 × 10 4 cells / mouse; (3) The model was established 8 weeks after the injection of hematopoietic stem cells.
[0029] Another object of the present invention is to provide an application of the Tslp transgenic animal model or spontaneous atopic dermatitis animal model obtained by the construction method of the present invention in the screening and evaluation of drugs for treating spontaneous atopic dermatitis.
[0030] Advantages of the present invention:
[0031] The experimental results showed that the spontaneous AD-like mouse model constructed by the method of the present invention spontaneously developed AD-like symptoms such as redness, swelling, peeling, and ulceration on the ears and back skin. The results of H&E pathological examination showed that compared with the control group, the skin lesions on the back and ears of the mice had epidermal hyperplasia and thickening of the stratum spinosum, accompanied by hyperkeratosis and parakeratosis in some areas, and the thickness of the epidermis increased significantly. In addition, by staining the back and ear skin with toluidine blue, the results showed that the mast cell infiltration in the mice in the model construction group was obvious and the number increased. Based on the existing observational experimental data, it is proved that the HSC-NCG-mTslp mouse model constructed by the present invention can effectively simulate the pathological characteristics and disease progression of clinical AD patients, and can also be used for the efficacy evaluation of AD-related drugs.
[0032] According to the characteristics of AD, it is very necessary to establish an animal model for research in order to deeply explore the pathogenic mechanism of AD and discover targeted intervention therapeutic drugs. However, there is no standardized method for preparing AD-like mouse models at home and abroad. The Nc / Nga mouse and Ds-NH mouse models developed by Japanese scholars are currently ideal spontaneous animal models for studying AD, but the spontaneous AD-like mice must be in a normal environment to stimulate AD symptoms. In a SPF-grade breeding environment without specific pathogens, the expected dermatitis symptoms will not appear, and no itching symptoms of mice are observed, which undoubtedly brings great inconvenience to the standardized and unified management of animals. In addition, exogenous chemical substances, dust mites, superantigens (Staphylococcus aureus enterotoxin), ovalbumin (OVA), capsaicin and other substances are used to induce AD, but the AD model constructed by this type of exogenous sensitization method cannot accurately reflect the relevant role of gene drive in the pathogenesis of AD, but is relatively focused on responding to the immune inflammatory response induced by exogenous antigens. In addition, although there are literature reports that transgenic mouse models such as IL4, IL-18 and IL-31 have been applied to preclinical AD research, the background of such transgenic mice is C57BL / 6 or BALB / c mice. Due to the inherent species differences between humans and mice, such models cannot objectively reflect the clinical manifestations of patients. Therefore, based on the comparison of existing AD model construction technologies, the HSC-NCG-mTslp mouse model constructed by the present invention can not only spontaneously develop AD-like symptoms in a standardized SPF-level environment, which is conducive to the unified standardized management of animals, but also can control the onset of the disease in a directional or targeted manner based on the humanized immune system from the DNA level, with strong purposefulness and closer to the pathological characteristics of clinical patients, making the pathogenic mechanism and efficacy experiments of atopic dermatitis more objective and scientific. This model also fills the gap in domestic AD transgenic model products. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 .Schematic diagram of the targeting sequence of NCG-mTslp transgenic mice.
[0034] Figure 2 .The results of restriction enzyme digestion identification of the targeting vector plasmid of NCG-mTslp transgenic mice.
[0035] Figure 3 .Results of identification of founder mice of NCG-mTslp transgenic mice
[0036] Figure 4 . Detection results of mTslp protein expression in NCG-mTslp transgenic mice
[0037] Figure 5 .Statistical results of lymph nodes in NCG-mTslp transgenic mice.
[0038] Figure 6 .Flow cytometry detection results of Th1, Th2 and Th17 in peripheral blood and spleen of HSC-NCG-mTslp mice.
[0039] Figure 7 .Total IgG of serum immunoglobulin in HSC-NCG-mTslp mice.
[0040] Figure 8 .Total IgM of serum immunoglobulin in HSC-NCG-mTslp mice.
[0041] Fig. 9 .Total IgE in serum immunoglobulins of HSC-NCG-mTslp mice.
[0042] Fig.10 .AD-like symptoms in the ears and back skin of HSC-NCG-mTslp mice.
[0043] Fig.11 .H&E pathological staining results of the ears and back skin of HSC-NCG-mTslp mice.
[0044] Fig.12 .Toluidine blue staining results of the ears and back skin of HSC-NCG-mTslp mice. DETAILED DESCRIPTION
[0045] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the reagents, materials and operating procedures used herein are reagents, materials and conventional procedures widely used in the corresponding fields.
[0046] The present invention is severe immunodeficiency NCG (NOD / ShiLtJGpt-Prkdc em26Cd52 Iq em26Cd22 Gpt) mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.
[0047] Example 1 Establishment of NCG-mTslp mouse model
[0048] 1. Solution design
[0049] Tslp is usually expressed in epithelial cells on the surface of lung, skin and intestinal barrier, and keratin 14 (K14) promoter is mainly expressed in epithelial cells. Therefore, mTslp CDS (423 bp, SEQ ID No: 1) was selected to be expressed under the drive of human K14 promoter. The schematic diagram of the targeting sequence is shown in Figure 1 The targeting sequence is shown in SEQ ID NO: 2.
[0050] 2. Vector Construction
[0051] 1) Amplify hk14 using VEGFR3-TG-Final as template;
[0052] 2) Amplify mTslp using mTslp CDS as template;
[0053] 3) Using Human GH CDS as template, high-fidelity PCR amplified hGH;
[0054] 4) Using pMD18-T as a template, amplify the pMD18-T vector;
[0055] 5) The above four fragments were slic-linked, and the successfully linked vector was named NCG-TSLP-final;
[0056] 6) Transform the above vector NCG-TSLP-final into competent Top10.
[0057] 7) Identification of positive clones.
[0058] 8) The positive clones were identified by bacterial culture, and the plasmids were further extracted for enzyme digestion identification. The selected restriction enzymes and corresponding bands (bp) are shown in Table 1.
[0059] Table 1 Restriction enzyme names and band sizes
[0060]
[0061] The results of enzyme digestion identification are as follows Figure 2 shown.
[0062] 3. Microinjection
[0063] DNA purification: NotI digestion and electrophoresis, recover the correct fragment (3658 bp fragment), purify and use for injection.
[0064] The purified target donor was injected into the 0.5-day fertilized eggs of NCG mice. The injected fertilized eggs were transplanted into the bodies of 0.5-day pseudo-pregnant female mice and the mice were waited for birth. The mice produced by the pseudo-pregnant recipient mice were identified by PCR to obtain the transgenic positive strains.
[0065] 4. Identification of transgenic mice
[0066] The genomic DNA of the founder mice obtained was subjected to PCR amplification analysis using the three pairs of primers in Table 2. If the DNA identification primers ①② identified positive results, it means that the mouse was target positive.
[0067] Table 2 Founder mouse genome PCR identification primers
[0068]
[0069]
[0070] PCR identification was performed using the primers in Table 2. After identification, 916#, 918#, 929#, 936#, 955#, 958#, 963#, and 966# were transgenic positive founder mice. The identification results are as follows: Figure 3 (The numbers are the mouse tail numbers, WT is the NCG wild type, N is the negative blank control, and M is the DNA Marker).
[0071] 5. Establishment and screening of transgenic mice
[0072] The above-mentioned NCG-mTslp transgenic positive founder mice 936#, 963#, and 918# were bred and established. During the breeding and establishment process, the expression of mTslp was preferentially detected in the founder mice with stable inheritance. Blood was collected from the mice, serum was separated (centrifuged at 1000g for 10 minutes), and Elisa experiments were performed. The results are as follows. Figure 4 As shown, the mTslp expression level of line918# was the highest among the three lines obtained.
[0073] Since the mTslp gene promotes the development of mouse lymph nodes, the transgenic mice were dissected to check the development of lymph nodes, such as Figure 5 As shown, line918# and line963# had significant effects on lymph node reconstruction.
[0074] Based on the above results, line918# was selected as the candidate line. Unless otherwise specified in the following text, NCG-mTslp TG mice are all line918#.
[0075] Example 2 Construction of the humanized immune system mouse model HSC-NCG-mTslp and feasibility study of spontaneous atopic dermatitis
[0076] 1) irradiating and myeloablating NCG mice of severe immunodeficiency at 3-4 weeks of age and the NCG-mTslp mouse model prepared in Example 1, respectively, with an irradiation dose of 100 cGy;
[0077] 2) Inject human CD34 into mice through tail vein + Hematopoietic stem cells (HSC), dose 5×10 4 / mouse;
[0078] 3) Blood was collected from the fundus vein 12-22 weeks after the injection of hematopoietic stem cells, and human IgG, IgM and IgE were tested by ELISA. The results were as follows Figure 7 , 8 , 9, the results showed that the expression levels of human IgG, IgM and IgE in the serum of mice in the HSC-NCG-mTslp group were higher than those in the HSC-NCG control group;
[0079] 4) Anticoagulated blood was collected 24 weeks after the injection of hematopoietic stem cells, and the mice were euthanized for photographing and sampling. The expression of Th1, Th2, and Th17 was detected by flow cytometry in anticoagulated blood and spleen. The results are as follows Figure 6 As shown, the results showed that the expression levels of Th2 and Th17 in mice in the HSC-NCG-mTslp group were significantly higher than those in the HSC-NCG control group.
[0080] 5) 24 weeks after the injection of hematopoietic stem cells, the mice were euthanized, the ears and back skin of each group of mice were taken, dehydrated and fixed, and then embedded in paraffin to make paraffin sections. Hematoxylin-eosin (HE) staining was used to observe the histological characteristics of the mouse skin lesions. Fig.10 The results showed that the ears and back skin of the HSC-NCG-mTslp group mice showed obvious AD-like symptoms such as erythema, peeling and even ulceration, while the HSC-NCG control group mice did not show related phenotypes. The results of H&E pathological staining of the ears and back skin of HSC-NCG-mTslp mice are shown in Figure 2. Fig.11As shown. The results showed that the back epidermis and dermis of the control group HSC-NCG mice had normal structures and normal cell morphology. The epidermis of the skin lesions of HSC-NCG-mTslp mice was hyperplastic, with hyperkeratosis and incomplete keratinization in some areas, and the thickness of the epidermis was significantly higher than that of the HSC-NCG control group. The epidermis of the ear skin of HSC-NCG-mTslp was thickened, and the squamous cells proliferated; diffuse moderate mixed inflammatory cell infiltration was seen in the dermis; the number of skin appendages-hair follicles, sebaceous glands, etc. was reduced. The epidermis of the ear skin of HSC-NCG mice in the control group was intact, without ulceration; no hyperplasia was observed in the dermis, and some blood vessels were slightly dilated; there was no hyperplasia or reduction of skin appendages; no abnormalities were found in the muscular layer, subcutaneous tissue, and cartilage.
[0081] 6) The paraffin sections of the mouse ears and back skin were stained with toluidine blue, and the number of mast cells was observed under an optical microscope. Fig.12 The results showed that compared with the HSC-NCG control group mice, the HSC-NCG-mTslp group mice had obvious mast cell infiltration and increased number.
[0082] In summary, atopic dermatitis, as a chronic recurrent inflammatory disease, has a high incidence rate in all races, causing huge mental and economic burdens on individuals and society. Over the years, in order to further understand the pathogenesis of AD and find AD therapeutic drugs, researchers have emerged a variety of AD mouse models. As mentioned above, these models have certain deficiencies in terms of standardized animal management or whether they can accurately reflect the role of gene drive in the pathogenesis of AD. The HSC-NCG-mTslp mouse model constructed by the present invention can spontaneously produce AD-like symptoms in a conventional standardized SPF-level environment; in addition, based on the humanized immune system, starting from the DNA level, the onset of the disease is controlled in a directed or targeted manner, which is highly purposeful and successfully avoids the inherent species differences between humans and mice, and is closer to the pathological characteristics of clinical patients, making the pathogenic mechanism and efficacy experiments of AD more objective and scientific.
Claims
1. A method for constructing a Tslp transgenic animal model, characterized in that Using gene editing technology, the Tslp gene was overexpressed in immunodeficient animals.
2. The construction method according to claim 1, characterized in that The gene editing technology includes one or more of homologous recombination, zinc finger nuclease technology, transcription activator-like effector nuclease technology, CRISPR / Cas9 system, and single base editing technology.
3. The construction method according to claim 1, characterized in that Gene editing technology is used to obtain transgenic targeting vectors, which are injected into animal fertilized eggs by microinjection, or ES cell targeting technology is used to transfect the targeting vector into animal ES cells, or retroviral infection method is used to recombinant the target gene into a retroviral vector to infect animal embryos before / after implantation, or sperm vector method is used to introduce the transgenic targeting vector into sperm through electroporation and then combine it with the egg.
4. The construction method according to claim 3, characterized in that The steps include: (1) Design and construct a targeting donor containing the protein coding region of the tslp gene; (2) injecting the targeting donor prepared in step (1) into the fertilized egg of an immunodeficient animal or transfecting it into the ES cell of an immunodeficient animal by microinjection, and randomly inserting the protein coding region of the tslp gene into the genome; (3) The fertilized egg is transplanted into a surrogate mother or the targeted positive ES cells are injected into the animal blastocyst and the blastocyst is transplanted into the surrogate mother for breeding. The offspring produced are the F0 generation animals. After the F0 generation animals with correct genotypes reach sexual maturity, they are bred with wild-type animals of the same background to obtain the F1 generation.
5. The construction method according to claim 4, characterized in that The protein coding region sequence of the Tslp gene is shown in SEQ ID NO:
1.
6. The construction method according to claim 5, characterized in that The targeting sequence has a keratin K14 promoter.
7. The construction method according to claim 6, characterized in that The targeting donor includes keratin promoter K14, mTslp CDS and transcription terminator.
8. The construction method according to claim 7, characterized in that The targeting donor is shown in SEQ ID NO:
2.
9. The construction method according to any one of claims 1 to 8, characterized in that The animal is a mammal.
10. The construction method according to claim 9, characterized in that The animal is a rodent.
11. The construction method according to claim 10, characterized in that The animal is a rat or a mouse.
12. The construction method according to claim 11, characterized in that The animals are severely immunodeficient mice NCG.
13. A method for constructing a spontaneous atopic dermatitis animal model, characterized in that The immune system of the Tslp transgenic animal model constructed by the method according to any one of claims 1 to 12 is reconstructed, and human stem cells with differentiation potential are transplanted into the model to construct a spontaneous atopic dermatitis animal model.
14. The construction method according to claim 13, characterized in that The immune system reconstruction is performed by bone marrow stem cell elimination or immunosuppression and immunoregulation using low-toxic drugs, and the stem cells with differentiation potential are one or more of bone marrow cells, fetal liver cells, hematopoietic stem cells, pluripotent stem cells, and induced pluripotent stem cells.
15. The construction method according to claim 14, characterized in that Immune system reconstitution involves the following steps: (1) 3-4 week old female Tslp transgenic severely immunodeficient mice NCG were irradiated with 100 cGy for myeloablation; (2) Human hematopoietic stem cells hCD34 + HSCs were inoculated into mice via the tail vein at a dose of 5 × 10 4 cells / mouse; (3) Modeling was completed 8 weeks after the injection of hematopoietic stem cells.
16. Use of the Tslp transgenic animal model constructed according to the method of any one of claims 1 to 12 or the spontaneous atopic dermatitis animal model constructed according to the method of any one of claims 13 to 15 in screening and evaluating drugs for treating spontaneous atopic dermatitis.
Citation Information
Cited By
Construction method of atopic dermatitis animal model
CN120731921A
Immune system humanized mutation vector, and construction method and application of humanized mouse model
CN122588165A
